<DOC>
	<DOCNO>NCT01419925</DOCNO>
	<brief_summary>`` Multimeric-001 '' ( M-001 ) recently develop , contain conserve , common linear influenza epitope activate cellular humoral arm immune system wide variety influenza A B strain . Apart direct action , M-001 attractive candidate prim immune response seasonal influenza vaccine elderly population . The current clinical study design ass M-001 's standalone prim action subject 65 year old . This second Phase II study comprise 120 participant . Eligible subject randomize receive receive either two sequential non-adjuvanted single non-adjuvanted single adjuvanted intramuscular injection 500 mcg M-001 ( treatment ) , one placebo ( saline ) injection , receive TIV .</brief_summary>
	<brief_title>A Study Assess Safety Immunogenicity M-001 Influenza Vaccine Primer TIV Elderly Volunteers</brief_title>
	<detailed_description>This two-center , randomize , placebo-controlled study . 120 subject randomize 1:1:1:1 four group receive either two sequential non-adjuvanted single non-adjuvanted single adjuvanted intramuscular injection 500 mcg M-001 ( treatment ) , one placebo ( saline ) injection , receive TIV . Due visual difference placebo treatment study partially blind . Hemagglutinin inhibition ( HAI ) evaluate baseline 3 week standard trivalent inactivate influenza vaccine ( TIV ) vaccination measure M-001 's efficacy . Cell mediate immune ( CMI ) responses also evaluated subject receive non-adjuvanted adjuvanted M-001 vaccination . The subject monitor safety throughout study .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males female age least 65 year old Eligible receive standard seasonal influenza vaccine accord MOH guideline . Subjects provide write informed consent participate study . Subjects able adhere visit schedule protocol requirement available complete study . Haematology , chemistry urinalysis value clinical significance reflect medical condition , accord physician 's judgment , might confound result study pose additional risk subject participation study . Male subject must agree use condom full term study period ( include follow ) female partner use acceptable contraceptive method . Subjects seronegative least one strain include seasonal vaccine influenza 2011 2012 Known history significant medical disorder , investigator 's judgment , might confound result study pose additional risk subject participation study . Subjects know Guillain Barr√© Syndrome past . Subjects immunized antiinfluenza vaccine infect influenza virus within eight month prior screen visit . Known hypersensitivity associate previous influenza vaccination . Use influenza antiviral medication within 4 week vaccination . Known hypersensitivity and/or allergy drug vaccine . Known hypersensitivity egg protein ( egg egg product ) , chicken protein , component commercial vaccine ( e.g. , formaldehyde , octoxinol 9 ( Triton X100 ) neomycin ) . Persons deficient produce antibody , whether due genetic defect , immunodeficiency disease , immunosuppressive therapy . History bleed disorder subject thrombocytopenia ( since bleeding may occur follow intramuscular administration subject ) . Any clinically significant abnormality upon physical examination clinical laboratory test screen visit , accord physician 's judgment , might confound result study pose additional risk subject participation study . Positive serology HIV , HCV antibody HBsAg . Any acute medical situation ( e.g . acute infection , ongoing flu symptom ) without fever within 48 hour vaccination , consider significant Investigator . Subjects participate another interventional clinical study within 30 day prior first dose Subjects noncooperative unwilling sign consent form .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>influenza vaccine</keyword>
	<keyword>peptide</keyword>
	<keyword>universal</keyword>
	<keyword>prime</keyword>
	<keyword>boost</keyword>
	<keyword>TIV</keyword>
	<keyword>HAI</keyword>
	<keyword>Hemagglutination Inhibition</keyword>
	<keyword>elderly</keyword>
</DOC>